To the Editor: Infl uenza A pandemic (H1N1) 2009 virus emerged in early 2009 in Mexico and has since spread worldwide. In Japan, the fi rst outbreak of the novel infl uenza was reported in May 2009 (1) and became pandemic in November. Although no cases of transfusion-transmitted infl uenza have been published, evidence exists of brief viremia before onset of symptoms (2, 3) . The possibility of transmission of this virus through transfusion of donated blood is of concern. The Japanese Red Cross Blood Centers have intercepted blood products with accompanying postdonation information indicating possible pandemic (H1N1) 2009 infection and attempted to identify the viral genome in those products by using nucleic acid amplifi cation technology (NAT).
During June-November 2009, blood samples were collected from plasma and erythrocyte products that had been processed from donations; postdonation information indicated diagnosis of pandemic (H1N1) 
Rapid Emergence of Oseltamivir Resistance
To (1) has caused at least 400,000 infections within 6 months; estimated mortality rate is 1.2% (2). Emergence of oseltamivir resistance in the pandemic (H1N1) 2009 virus is a rising challenge to global control of the pandemic. So far, 39 oseltamivir-resistant pandemic (H1N1) 2009 viruses have been reported worldwide (3). Among the 32 resistant strains reported in October 2009, a total of 13 (41%) were associated with postexposure chemoprophylaxis and 16 (50%) were from samples of patients receiving oseltamivir (3). We report rapid emergence of resistance (H275Y mutation) in a patient, 4 days after early treatment with standard doses of oseltamivir for pandemic (H1N1) 2009 pneumonia.
On September 1, 2009, a 20-yearold man with mental retardation consulted the emergency department of Kaohsiung Veterans General Hospital after 1 day of fever, sore throat, and nonproductive cough. A rapid diagnostic antigen test (Quick Vue Infl uenza test; Quidel, San Diego, CA, USA) showed the man to be positive for infl uenza A. He was hospitalized for bilateral pneumonitis and treated with oseltamivir (75 mg 2×/day for 5 days), ampicillin/sulbactam, and erythromycin. However, a progressive increase in bilateral perihilar interstitial infi ltration developed on the third day, accompanied by increasing dyspnea. Infl uenza A pandemic (H1N1) 2009 virus was isolated from the patient's nasopharyngeal secretions on days 1 and 4 by using MDCK cells. After DNA sequence analysis of the neuraminidase gene, the mutation of H275Y was not found in the fi rst isolate, but sequence analysis of the second isolate detected mixed populations (C/T) in the 823-nt position of the neuraminidase gene. Only a single pattern (T) was found from the cultured viruses, indicating a mixed quasispecies of oseltamivir-resistant and -susceptible viruses emerging after 4 days of oseltamivir treatment. The oseltamivirresistant viruses become dominant in the cell culture-propagated viruses. Chan et al. reported a similar case in which the original clinical specimens contained a mixed population of variants, and oseltamivir-resistant viruses become dominant after the passage in MDCK cells (4) .
On his 9th day in the hospital, the patient was intubated because of acute respiratory distress syndrome (Figure) and given levofl oxacin. Urine samples were negative for Pneumococcus and Legionella spp. antigens. The patient improved and was extubated on hospital day 16.
Paired serologic test results were negative for Mycoplasma pneumoniae and Legionella spp. antibody; however, immunoglobulin G for Chlamydia pneumoniae increased 4-fold. By 37 days after illness onset, clinical signs and symptoms resolved and bilateral lineoreticular infi ltration was reduced.
On August 8, 2009, Taiwan had the most devastating typhoon (Typhoon Morakot) in 50 years. The patient reported here had stayed in a typhoon evacuation camp for 1 week before his infl uenza signs and symptoms developed. Although 4 sporadic cases of pandemic (H1N1) 2009 infections were reported from the same camp, none of the isolated viruses harbored the H275Y mutation in the neuraminidase gene. No evidence of virus transmission was found among healthcare personnel, family members, and camp members who had been in close contact with the patient.
Oseltamivir has been recommended by the US Centers for Disease Control and Prevention for the treatment of 
